XML 19 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 20, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 001-40901    
Entity Registrant Name LUCID DIAGNOSTICS INC.    
Entity Central Index Key 0001799011    
Entity Tax Identification Number 82-5488042    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 360 Madison Avenue    
Entity Address, Address Line Two 25th Floor    
Entity Address, City or Town New York    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10017    
City Area Code (917)    
Local Phone Number 813-1828    
Title of 12(b) Security Common Stock, $0.001 par value per share    
Trading Symbol LUCD    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 14.6
Entity Common Stock, Shares Outstanding 66,969,390 90,753,851  
Documents Incorporated by Reference [Text Block] Portions of the registrant’s definitive proxy statement for its 2025 annual meeting of stockholders are incorporated by reference into Part III of this Form 10-K where indicated. Such definitive proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the year ended December 31, 2024    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.001    
Auditor Firm ID 688    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of Lucid Diagnostics Inc. and Subsidiaries (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders’ equity (deficit) and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.    
Auditor Name Marcum LLP    
Auditor Location New York, NY